Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market Seite 1
31.01.2024 - BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) - TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from ... Seite 1
Source: wallstreet-online.de